Treatment of diseases caused by parasites;Tratamiento de las enfermedades causadas por parásitos

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 28, Issue 1, 2010, Pages 44-59

  Pérez Molina, José Antonio ^a   Díaz Menéndez, Marta ^a   Pérez Ayala, Ana ^a   Ferrere, Federico ^a   Monje, Begoña ^a   Norman, Francesca ^a   López Vélez, Rogelio ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Antiparasitic agents; Parasites; Review

Indexed keywords

ALBENDAZOLE; AMPHOTERICIN B; ANTIPARASITIC AGENT; AZITHROMYCIN; CHLORHEXIDINE; CHLOROQUINE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DIIODOHYDROXYQUIN; DILOXANIDE FUROATE; EMETINE; FLUCONAZOLE; FLUCYTOSINE; FUMAGILLIN; FURAZOLIDONE; ITRACONAZOLE; MEGLUMINE ANTIMONATE; MEPACRINE; METRONIDAZOLE; MICONAZOLE; NITAZOXANIDE; ORNIDAZOLE; PAROMOMYCIN; PENTAMIDINE; PRIMAQUINE; PYRIMETHAMINE; STIBOGLUCONATE SODIUM; SULFADIAZINE; TETRACYCLINE DERIVATIVE; TINIDAZOLE; UNINDEXED DRUG;

ACANTHAMOEBA; ACANTHAMOEBA ENCEPHALITIS; AFRICAN TRYPANOSOMIASIS; AMEBIASIS; ARTICLE; BALANTIDIASIS; BALANTIDIUM; BRUGIA MALAYI; CESTODIASIS; COCCIDIAL INFECTION; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM HOMINIS; CRYPTOSPORIDIUM PARVUM; CYCLOSPORIASIS; CYSTICERCOSIS; ECHINOCOCCOSIS; ENCEPHALITOZOON INTESTINALIS; ENCEPHALITOZOONOSIS; ENDOLIMAX NANA; ENTAMOEBA; ENTAMOEBA COLI; ENTAMOEBA DISPAR; ENTAMOEBA GINGIVALIS; ENTAMOEBA HARTMANNI; ENTAMOEBA HISTOLYTICA; ENTAMOEBA MOSHKOVSKII; ENTEROCYTOZOON; ENTEROCYTOZOON INFECTION; FILARIASIS; GIARDIA LAMBLIA; GIARDIASIS; HIGH RISK PATIENT; HUMAN; INCIDENCE; IODAMOEBA BUTSCHLII; ISOSPORA BELLI; ISOSPORIASIS; LEISHMANIASIS; MALARIA; MANSONELLA OZZARDI; MANSONELLA PERSTANS; MICROSPORIDIA; MICROSPORIDIOSIS; MORBIDITY; MORTALITY; NEMATODIASIS; PARASITE; PARASITOLOGY; PARASITOSIS; PLASMODIUM FALCIPARUM; PLASMODIUM KNOWLESI; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PLASMODIUM VIVAX; PROPHYLAXIS; SARCOCISTIOSIS; SARCOCYSTIS; SPAIN; SPARGANOSIS; TOXOPLASMOSIS; TRAVEL; TREATMENT DURATION; TREATMENT INDICATION; TREMATODIASIS; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; TRYPANOSOMA; WUCHERERIA BANCROFTI;

ANIMALS; ANTIPARASITIC AGENTS; ECTOPARASITIC INFESTATIONS; EMIGRANTS AND IMMIGRANTS; HELMINTHIASIS; HUMANS; IMMUNOCOMPROMISED HOST; INTESTINAL DISEASES, PARASITIC; PARASITIC DISEASES; PROTOZOAN INFECTIONS; SPAIN; TRAVEL; ZOONOSES;

EID: 73249152431     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2009.11.003     Document Type: Article

References (52)

1. Stanley Jr. S.L. Amoebiasis. Lancet 361 (2003) 1025-1034
2. Fung H.B., and Doan T.L. Tinidazole: A nitroimidazole antiprotozoal agent. Clin Ther 27 (2005) 1859-1884
3. Abramowicz M. Drugs for parasitic infections. Medical Letter 5 (2007) e1-e15
4. Gathiram V., and Jackson T.F. A longitudinal study of asymptomatic carriers of pathogenic zymodemes of Entamoeba histolytica. S Afr Med J 72 (1987) 669-672
5. Akgun Y., Tacyildiz I.H., and Celik Y. Amebic liver abscess: Changing trends over 20 years. World J Surg 23 (1999) 102-106
6. Schuster F.L., and Ramírez-Ávila L. Current world status of Balantidium coli. Clin Microbiol Rev 21 (2008) 626-638
7. Abubakar I., Aliyu S.H., Arumugam C., Usman N.K., and Hunter P.R. Treatment of cryptosporidiosis in immunocompromised individuals: Systematic review and meta-analysis. Br J Clin Pharmacol 63 (2007) 387-393
8. Abubakar I., Aliyu S.H., Arumugam C., Hunter P.R., and Usman N.K. Prevention and treatment of cryptosporidiosis in immunocompromised patients. Cochrane Database Syst Rev (2007) CD004932
9. Hanevik K., Morch K., Eide G.E., Langeland N., and Hausken T. Effects of albendazole/metronidazole or tetracycline/folate treatments on persisting symptoms after Giardia infection: A randomized open clinical trial. Scand J Infect Dis 40 (2008) 517-522
10. Wendel K.A., and Workowski K.A. Trichomoniasis: Challenges to appropriate management. Clin Infect Dis 44 (2007) S123-S129
11. Schuster F.L., and Visvesvara G.S. Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals. Int J Parasitol 34 (2004) 1001-1027
12. Visvesvara G.S., Moura H., and Schuster F.L. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp. Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol Med Microbiol 50 (2007) 1-26
13. Aichelburg A.C., Walochnik J., Assadian O., Prosch H., Steuer A., Perneczky G., et al. Successful treatment of disseminated Acanthamoeba sp. infection with miltefosine. Emerg Infect Dis 14 (2008) 1743-1746
14. Global Malaria Programme. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2006, (WHO/HTM/MAL/2006.1108)
15. Dondorp A.M., Nosten F., Yi P., Das D., Phyo A.P., Tarning J., et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361 (2009) 455-467
16. Centers for Disease Control and Prevention. Treatment of Malaria (Guidelines for clinicians) [consultado 25/9/2009]. Disponible en: www.cdc.gov/malaria/diagnosis_treatment/tx_clinicians.htm
17. Villar J.C., Marín-Neto J.A., Ebrahim S., and Yusuf S. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev (2002) CD003463
18. OMS. Reporte sobre la enfermedad de Chagas. 17-20 de abril de 2005. Buenos Aires (Argentina) [consultado 20/7/2007]. Disponible en: http://www.who.int/tdrwww.who.int/tdr
19. Rodriques Coura J., and de Castro S.L. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 97 (2002) 3-24
20. Pérez-Molina JA, Pérez-Ayala A, Moreno S, Fernández-González MC, Zamora J, López-Vélez R. Use of benznidazole to treat chronic Chagas' disease: A systematic review with a meta-analysis. J Antimicrob Chemother. 2009;64:1139-47.
21. Kennedy P.G. The continuing problem of human African trypanosomiasis (sleeping sickness). Ann Neurol 64 (2008) 116-126
22. Bisser S., N'Siesi F.X., Lejon V., Preux P.M., Van Nieuwenhove S., Miaka Mia Bilenge C., et al. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. J Infect Dis 195 (2007) 322-329
23. Priotto G., Kasparian S., Mutombo W., Ngouama D., Ghorashian S., Arnold U., et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374 (2009) 56-64
24. Murray H.W., Berman J.D., Davies C.R., and Saravia N.G. Advances in leishmaniasis. Lancet 366 (2005) 1561-1577
25. Olliaro P.L., Guerin P.J., Gerstl S., Haaskjold A.A., Rottingen J.A., and Sundar S. Treatment options for visceral leishmaniasis: A systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 5 (2005) 763-774
26. Montoya J.G., and Liesenfeld O. Toxoplasmosis. Lancet 363 (2004) 1965-1976
27. Panel de Expertos de Grupo de Estudio del Sida; Plan Nacional sobre el Sida. Prevención de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el VIH en el año 2008. Recomendaciones del Grupo de Estudio del Sida (GESIDA)/Plan Nacional sobre el Sida. Enferm Infecc Microbiol Clin 26 (2008) 437-464
28. Panel de expertos de GESIDA; Plan Nacional sobre el Sida. Tratamiento de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el virus de la inmunodeficiencia humana en la era del tratamiento antirretroviral de gran actividad. Recomendaciones del Grupo de Estudio del Sida (GESIDA)/Plan Nacional sobre el Sida. Enferm Infecc Microbiol Clin 26 (2008) 356-379
29. Soheilian M., Sadoughi M.M., Ghajarnia M., Dehghan M.H., Yazdani S., Behboudi H., et al. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology 112 (2005) 1876-1882
30. Montoya J.G., and Remington J.S. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis 47 (2008) 554-566
31. Wormser G.P., Dattwyler R.J., Shapiro E.D., Halperin J.J., Steere A.C., Klempner M.S., et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: Clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 43 (2006) 1089-1134
32. Keiser J., and Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: Systematic review and meta-analysis. JAMA 299 (2008) 1937-1948
33. Bethony J., Brooker S., Albonico M., Geiger S.M., Loukas A., Diemert D., et al. Soil-transmitted helminth infections: Ascariasis, trichuriasis, and hookworm. Lancet 367 (2006) 1521-1532
34. Dickson R, Awasthi S, Demellweeck C, Williamson P. Deworming drugs for treating soil-transmitted intestinal worms in children: Effects on growth and school performance. Cochrane Database Syst Rev. 2007, Issue 4. Art. No.: CD000371. DOI:10.1002/14651858.CD000371.pub3.
35. Specht S., Mand S., Marfo-Debrekyei Y., Debrah A.Y., Konadu P., Adjei O., et al. Efficacy of 2- and 4-week rifampicin treatment on the Wolbachia of Onchocerca volvulus. Parasitol Res 103 (2008) 1303-1309
36. Hoerauf A. Filariasis: New drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr Opin Infect Dis 21 (2008) 673-681
37. Boussinesq M. Onchocerciasis control: Biological research is still needed. Parasite 15 (2008) 510-514
38. Ardelli B.F., and Prichard R.K. Identification of variant ABC-transporter genes among Onchocerca volvulus collected from ivermectin-treated and untreated patients in Ghana, West Africa. Ann Trop Med Parasitol 98 (2004) 371-384
39. Bregani E.R., Rovellini A., Mbaidoum N., and Magnini M.G. Comparison of different anthelminthic drug regimens against Mansonella perstans filariasis. Trans R Soc Trop Med Hyg 100 (2006) 458-463
40. Coulibaly Y., Dembele B., Diallo A., Lipner E., Doumbia S., Coulibaly S., et al. A randomized trial of doxycycline for Mansonella perstans infection. New Engl J Med 361 (2009) 1448-1458
41. Utzinger J., N'Goran E.K., N'Dri A., Lengeler C., Xiao S., and Tanner M. Oral artemether for prevention of Schistosoma mansoni infection: Randomised controlled trial. Lancet 355 (2000) 1320-1325
42. Harinasuta T., Pungpak S., and Keystone J.S. Trematode infections. Opisthorchiasis, clonorchiasis, fascioliasis, and paragonimiasis. Infect Dis Clin North Am 7 (1993) 699-716
43. Keiser J., Engels D., Buscher G., and Utzinger J. Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Investig Drugs 14 (2005) 1513-1526
44. PAIR: Puncture, aspiration, injection, re-aspiration, an option for the treatment of Cystic Echinococcosis. Geneva: World Health Organization; 2001 (WHO/CDS/CSR/APH/2001
45. Vuitton D.A. Benzimidazoles for the treatment of cystic and alveolar echinococcosis: What is the consensus?. Expert Rev Anti Infect Ther 7 (2009) 145-149
46. Stamatakos M., Sargedi C., Stefanaki C., Safioleas C., Matthaiopoulou I., and Safioleas M. Anthelminthic treatment: An adjuvant therapeutic strategy against Echinococcus granulosus. Parasitol Int 58 (2009) 115-120
47. García H.H., Del Brutto O.H., Nash T.E., White Jr. A.C., Tsang V.C., and Gilman R.H. New concepts in the diagnosis and management of neurocysticercosis (Taenia solium). Am J Trop Med Hyg 72 (2005) 3-9
48. Garg R.K., Potluri N., Kar A.M., Singh M.K., Shukla R., Agrawal A., et al. Short course of prednisolone in patients with solitary cysticercus granuloma: A double blind placebo controlled study. J Infect 53 (2006) 65-69
49. Del Brutto O.H., Roos K.L., Coffey C.S., and Garcia H.H. Meta-analysis: Cysticidal drugs for neurocysticercosis: Albendazole and praziquantel. Ann Intern Med 145 (2006) 43-51
50. Góngora-Rivera F., Soto-Hernández J.L., González Esquivel D., Cook H.J., Márquez-Caraveo C., Hernández Dávila R., et al. Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis. Neurology 66 (2006) 436-438
51. García H.H., González A.E., Evans C.A., and Gilman R.H. Taenia solium cysticercosis. Lancet 362 (2003) 547-556
52. Leone P.A. Scabies and pediculosis pubis: An update of treatment regimens and general review. Clin Infect Dis 44 (2007) S153-S159